Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stem cell versus triamcinolone injection for knee osteoarthritis
IRCT20151017024572N19Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mesenchymal stem cells, triamcinolone and lidocaine in knee osteoarthritis (OA) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Pain intensity by visual analog scale at 6 months, WOMAC score at 6 months and 2 more. Started Feb 2019; status: completed.
02
Drugs
mesenchymal stem cellstriamcinolonelidocaine
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on IRCT20151017024572N19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151017024572N19.